

**Amendment #1
to RFP-NIH-NIAID-DAIDS-02-20**

**"Drug Development for Opportunistic Infections – Pneumocystis Carinii
Pneumonia**

Amendment to Solicitation No.:	NIH-NIAID-DAIDS-02-20
Amendment No.:	1
Amendment Date:	Thursday, September 13, 2001
RFP Issue Date:	Wednesday, July 25, 2001
Proposal Due Date:	Thursday, October, 25,2001 (Unchanged)
Issued By:	Paul D. McFarlane Contracting Officer NIH/NIAID Contract Management Branch 6700-B Rockledge Drive Room 2230, MSC 7612 Bethesda, Maryland 20892-7612
Point of Contact:	Elizabeth Osinski, Contract Specialist
Name and Address of Offeror:	To All Potential Offerors

The above numbered solicitation is amended as set forth below:

To correspond with **Statement of Work**, item 2.c., "Evaluation of treatment therapies in a RAT model," an item 2.C. is added to NOTE 2 to OFFEROR as set forth below. The entire NOTE is reprinted below for clarity.

[NOTE 2 TO OFFEROR: Offerors shall document the current availability of laboratory, mouse and rat systems, suitable for these additional studies. Offerors shall describe in detail the technical approach, models, protocols, and data analysis proposed for these studies, and provide documentation of the standardization and reproducibility of any alternative model systems proposed.]

At the present time, the Government does not know how many additional studies will be needed. For purposes of preparing a cost proposal, Offerors shall assume that 1 therapy per year will require studies 2.A., and 2.B. as described below:

- A. EVALUATION OF 2 INDIVIDUAL DRUGS IN COMBINATION AT 3 DOSAGES FOR TREATMENT EFFICACY;**
- B. COMPARISON EFFICACY OF 3 DOSAGE LEVELS ADMINISTERED TWICE PER DAY BY GAVAGE AND BY INTRAVENOUS OR INTRAPERITONEAL INJECTION.**

For purposes of preparing a cost proposal for the RAT model in Item 2.c. of the Statement of Work, the Offeror shall assume 2 therapies per year will require study as described below:

- C. EVALUATION OF THE THERAPEUTIC EFFICACY OF 2 DRUGS AT 3 DOSAGE LEVELS COMPARED TO A POSITIVE CONTROL THERAPY AND A NEGATIVE CONTROL]**

If, by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram, letter or e-mail, provided each telegram, letter or e-mail makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

Except as provided herein, all terms and conditions of the RFP document NIH-NIAID-DAIDS 02-20 remain unchanged and in full force and effect.

The hour and date specified for receipt of offers is **NOT** extended.

Offerors must acknowledge receipt of this Amendment #1, by the following method:

- By acknowledging receipt of the amendment on each copy of the offer submitted.

Failure to receive your acknowledgment of this amendment may result in the rejection of your offer.

[Top](#) | [RFP-NIH-NIAID-DAIDS-02-20](#)

[NIAID Contracts Home](#) | [NIH RFP Directory](#) | [NIH Home](#)